Navigation Links
Verenium Announces Signing of Lease for New Office and Lab Space
Date:6/29/2011

Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statem
'/>"/>
SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes
2. Verenium Receives CLARUS Award at MDB Capitals Bright Lights Conference 2011
3. Verenium to Present at Upcoming Conferences
4. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
5. Verenium to Present at MDB Capital Groups Bright Lights Conference
6. Verenium Announces Debt Repurchase
7. Worlds Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Vereniums Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval
8. Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results
9. Verenium to Present at Jefferies 11th Global Clean Technology Conference
10. Verenium Announces Favorable Outcome of Capital Ventures International Lawsuit
11. Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 /PRNewswire/ ... company advancing patient care in critical areas, announced the ... of common stock, and warrants to purchase up to ... offering price of $4.00 per share and $.01 per ... of $5.00, are exercisable immediately, and expire 5 years ...
(Date:12/24/2014)... 2014 “Preparative & Process Chromatography ... Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, ... - Forecasts to 2019” provides a detailed overview ... market trends, and strategies impacting the preparative and ... forecasts of the revenue and share analysis. ...
(Date:12/24/2014)... SoundConnect’s 2015 ... introduce cutting edge communication technology, provide continued ... platform upgrades. This webinar series demonstrates online ... their quest to leverage web conferencing’s most ... SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our webinars ...
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... Oct. 21 (11:00 PM PT,Oct. 20) -- ... that,Novartis AG has agreed to acquire from Nektar ... $115 million in cash., "This agreement will ... development,of novel therapeutics using our PEGylation and conjugate ...
... riddled with defects, bulk crystalline materials never achieve their ... small there,s no room for defects. ("Nano" is short ... nanocrystalline materials may approach ideal strength in their resistance ... ability to withstand large internal strains before they fail. ...
... With limited information on,actual return on ... Education activities, pharmaceutical, biotechnology and medical,device industry ... of CME,support and strategies for ensuring investments ... patient outcomes. In the recently,published report by ...
Cached Biology Technology:Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 2Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 3Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 4Engineering nanoparticles for maximum strength 2Engineering nanoparticles for maximum strength 3Engineering nanoparticles for maximum strength 4Bio-Pharma Industry Improves Patient Outcomes Through Continuing Medical Education (CME) 2
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/10/2014)... California , December 9, 2014 ... with ITN,s BCARD Platform   ... cloud-based enterprise meeting scheduling solutions for business-to-business (B2B) ... the world leader in mobile near-field communication (NFC), ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... researchers at the Department of Energy,s BioEnergy Science Center ... ethanol production capacity in a microorganism. This discovery could ... produce higher concentrations of ethanol at lower costs. ... scientific discoveries of its labs and research centers to ...
... of General Medical Sciences, part of the National Institutes ... Infectious Disease Agent Study for a research project at ... Stephen Eubank, professor. Infectious diseases pose one of ... Models of Infectious Disease Agent Study (MIDAS) is a ...
... essential in the fight against,breast cancer. As described in ... this organ represents an excellent model system for investigation ... body. The branching morphogenesis that occurs during puberty and ... that occur in many tissues during embryogenesis and are ...
Cached Biology News:Single, key gene discovery could streamline production of biofuels 2National Institutes of Health renews successful infectious disease research study 2National Institutes of Health renews successful infectious disease research study 3
... or with significant secondary structure are often ... to PCR result in little or no ... increased by the addition of enhancing agents ... effective PCR enhancer for GC-rich templates., Polymer-Aide ...
... patented MasterAmp™ 10X PCR Enhancer (with ... allows improved sensitivity and specificity for ... MasterAmp™ PCR Enhancer in PCR eliminates ... melting, increases enzyme?s thermal stability, suppresses ...
... crate" style strip holder is designed for ... Linkage: This CLS number is a new ... product number. If showing no availability yet, ... (Z71,456-9) or contact customer service for assistance. ...
... use with 96- or 384-well PCR plates Dimples ... location on 96-tube plates End tabs on Thermo-Mat™ ... plate* Efficient sealing is achieved with either Thermo-Mat™ ... or clip-down hot lid thermal cyclers Fully autoclavable ...
Biology Products: